AstraZeneca’s tozorakimab meets primary endpoint in pivotal Phase III MIRANDA COPD trial

 

Tozorakimab delivered a statistically significant, clinically meaningful reduction in moderate-to-severe COPD exacerbations in the MIRANDA trial

Phase III MIRANDA results support planned regulatory submissions for tozorakimab as a potential first-in-class biologic therapy

https://finviz.com/quote.ashx?t=AZN&p=d

Hello! Chat with our bot to learn more about i